A Vaccine Against Group B Streptococcus: Recent Advances
C Carreras-Abad, L Ramkhelawon… - Infection and drug …, 2020 - Taylor & Francis
Group B streptococcus (GBS) causes a high burden of neonatal and infant disease globally.
Implementing a vaccine for pregnant women is a promising strategy to prevent neonatal and …
Implementing a vaccine for pregnant women is a promising strategy to prevent neonatal and …
[HTML][HTML] Proof of concept for a single-dose Group B Streptococcus vaccine based on capsular polysaccharide conjugated to Qβ virus-like particles
F Carboni, R Cozzi, G Romagnoli, G Tuscano… - npj Vaccines, 2023 - nature.com
A maternal vaccine to protect neonates against Group B Streptococcus invasive infection is
an unmet medical need. Such a vaccine should ideally be offered during the third trimester …
an unmet medical need. Such a vaccine should ideally be offered during the third trimester …
Development and validation of a 6-plex Luminex-based assay for measuring human serum antibodies to group B streptococcus capsular polysaccharides
MA Gaylord, M Larrier… - Human Vaccines & …, 2024 - Taylor & Francis
ABSTRACT Six serotypes (Ia, Ib, II, III, IV, and V) cause nearly all group B streptococcal
(GBS) disease globally. Capsular polysaccharide (CPS) conjugate vaccines aim to prevent …
(GBS) disease globally. Capsular polysaccharide (CPS) conjugate vaccines aim to prevent …
Safety and immunogenicity of a second dose of an investigational maternal trivalent group B Streptococcus vaccine in nonpregnant women 4–6 years after a first dose …
G Leroux-Roels, Z Bebia, C Maes… - Clinical Infectious …, 2020 - academic.oup.com
Background Maternal immunization against group B streptococcus (GBS) could protect
infants from invasive GBS disease. Additional doses in subsequent pregnancies may be …
infants from invasive GBS disease. Additional doses in subsequent pregnancies may be …
[HTML][HTML] Sublingual immunisation with GBS serotype III capsular polysaccharide-tetanus toxoid conjugate vaccine induces systemic and mucosal antibody responses …
MD Yousif, A Felek, M Saydam, S Wilson, S Murdan… - Vaccine, 2022 - Elsevier
No vaccines are currently licensed against Group B streptococcus (GBS), an important
cause of morbidity and mortality in babies and adults. Using a mouse model, and in vitro …
cause of morbidity and mortality in babies and adults. Using a mouse model, and in vitro …
[HTML][HTML] Development and validation of enzyme-linked immunosorbent assay for Group B Streptococcal polysaccharide vaccine
AY Jang, MJ Choi, Y Zhi, HJ Ji, JY Noh, JG Yoon… - Vaccines, 2021 - mdpi.com
Streptococcus agalactiae (group B Streptococcus, GBS) is a leading cause of neonatal
sepsis and meningitis in infants. Limitations of prenatal GBS screening and intrapartum …
sepsis and meningitis in infants. Limitations of prenatal GBS screening and intrapartum …